



Supplementary Figures and Figure Legends



Supplementary Figure 1. Over-expression or knock-down of miR-146a in brain endothelium. **(A)** Over-expression of miR-146a in hCMEC/D3 cells via transfection with Pre-miR-146a using siPORT. **(B)** Knock-down of miR-146a in hCMEC/D3 cells via transfection with Anti-miR-146a using lipofectamine 2000. Expression of miR-146a was analysed using Taqman quantitative RT-PCR and normalized to the small nuclear RNA U6B, expressed as relative level to scrambled control. Data represent mean \pm s.e.m. $n = 3$, ** $P < 0.01$, *** $P < 0.001$ via Student t test. **(C)** Photomicrograph demonstrating transfection efficiency via Cy3 tagged scrambled Pre-miR. Scale bar, 50 μm .




Supplementary Figure 2. Two known targets ROCK1 and STAT1 are not affected by miR-146a in brain endothelial cell. Western blot analysis show that over-expression of miR-146a via transfection with Pre-miR-146a did not repress the expression of ROCK1 and STAT1 in hCMEC/D3 cells either unstimulated or stimulated with cytokines (1 ng/ml TNF α /INF γ) for 0.5, 6 and 24 h.



Supplementary Figure 3. Small interference RNAs knock-down the expression of IRAK, TRAF6, NFAT5 and RhoA in brain endothelium. **(A)** Western blot analysis show that siIRAK1 or siTRAF6 repressed the expression of IRAK1 and TRAF6 respectively in hCMEC/D3 cells either unstimulated or stimulated with cytokines for 0.5, 6 and 24 h. **(B)** Western blot analysis show that co-transfection of siIRAK1 and siTRAF6 in hCMEC/D3 cells decreased simultaneously the expression of IRAK1 and

TRAF6 in cells untreated or treated with 1 ng/ml TNF α /INF γ for 0.5, 6 and 24 h. (C)
Western blot analysis show that siNFAT5 or siRhoA suppressed the expression of
NFAT5 and RhoA respectively in hCMEC/D3 cells either non-stimulated or cytokine-
stimulated for 0.5, 6 and 24 h. siRNA -, siControl; siRNA +, siIRAK1, or siTRAF6,
or siIRAK1 + siTRAF6, or siNFAT5, or siRhoA.



Supplementary Figure 4. IL1 receptor antagonist does not inhibit TNF α and INF γ induced NF κ B activation and leukocyte adhesion. **(A)**, hCMEC/D3 cells were treated with 0-100 ng/ml IL1 receptor antagonist (IL1ra) for 30 min before further treatment with 1 ng/ml TNF α /INF γ or 200 pg/ml IL1 β for 24 h, subject to immunocytochemistry of NF κ B p65. Percentage of cells with nuclear NF κ B was analysed. Data represent mean \pm s.e.m. n = 3, * P < 0.05, ** P < 0.01 compared with that treated with IL1 β but untreated with IL1ra via Student t test. **(B)**, hCMEC/D3 cells in 6-channel slides were treated with 50 ng/ml IL1ra for 30 min, and left untreated or treated with 1 ng/ml TNF α /INF γ or IL1 β for 24 h, exposed to Jurkat T cells for 5 min at 0.5 dyn/cm². Data represent mean \pm s.e.m. n = 4, * P < 0.05 compare with that treated with IL1 β but untreated with IL1ra via Student t test.

Supplementary Video Legends:

miR146a modulates Jurkat T cell adhesion to cytokine-stimulated hCMEC/D3 cells.

hCMEC/D3 cells in 6-channel slides were transfected with scrambled Pre-miR (**Video. A and B**), or Pre-miR-146a (**Video. C**), and left untreated (**Video. A**) or treated with 1 ng/ml TNF α and IFN γ (**Video. B and C**) for 24 h. hCMEC/D3 cells were then exposed to 5-chloromethylfluorescein diacetate (CMFDA)-labelled Jurkat T cells for 5 min at 0.5 dyn/cm². Note that Pre-miR-146a markedly decreased Jurkat T cells adherent to cytokine-activated brain endothelium. Images were recorded at one frame (640 x 480 μm^2 /field) per second with an inverted time-lapse fluorescence microscope (Olympus IX70, Tokyo, Japan) by using Image Pro Plus software (Media Cybernetics Inc., Bethesda, USA).